Amphastar Pharmaceuticals
AMPH
116 hedge funds and large institutions have $388M invested in Amphastar Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 42 increasing their positions, 36 reducing their positions, and 9 closing their positions.
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
17% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 36
6% more funds holding
Funds holding: 109 → 116 (+7)
0.35% less ownership
Funds ownership: 44.94% → 44.59% (-0.35%)
2% less capital invested
Capital invested by funds: $397M → $388M (-$9.83M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$4.92M |
| 2 |
MSL
Mackay Shields LLC
New York
|
+$4.3M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.4M |
| 4 |
Morgan Stanley
New York
|
+$1.22M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.85M |
| 3 |
JP Morgan Chase
New York
|
-$2.85M |
| 4 |
BlackRock
New York
|
-$2.12M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.18M |
AMPH Hedge Fund Activity: Q1 2018 in Review
116 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2018, worth a combined $388M — down 2.5% from $397M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AMPH positions and 9 closed out — a net gain of 8 holders — while 42 added to existing stakes and 36 trimmed.
The largest buyer was Cortina Asset Management, opening a new position worth an estimated $4.92M. The largest seller was Millennium Management, cutting an estimated $4.7M.
- 116 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2018, up from 109 in Q4 2017.
- Funds reported $388M of Amphastar Pharmaceuticals stock for Q1 2018, down 2.5% quarter-over-quarter.
- 17 funds opened new Amphastar Pharmaceuticals positions in Q1 2018 and 9 closed out, a net change of +8 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2018 was Cortina Asset Management, an estimated $4.92M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2018 was Millennium Management, an estimated $4.7M sold.
Based on aggregated 13F filings for Q1 2018.